Table 4.
Tryptophan showed a significant association with rapid progression in diabetic nephropathy after adjusting with other confounding factors
| Models | Multivariate | |
|---|---|---|
| Odds ratio (95% confidence interval) | P‐value | |
| Unadjusted model | 0.915 (0.848–0.986) | 0.021a |
| Model 1 (sex) | 0.908 (0.840–0.982) | 0.015a |
| Model 2 (age) | 0.880 (0.798–0.970) | 0.010a |
| Model 3 (duration of diabetes) | 0.882 (0.799–0.973) | 0.013a |
| Model 4 (HbA1c) | 0.873 (0.786–0.970) | 0.011a |
| Model 5 (Hb) | 0.822 (0.703–0.961) | 0.014a |
| Model 6 (UACR) | 0.836 (0.703–0.994) | 0.042a |
| Model 7 (use of ACEI or ARB) | 0.734 (0.571–0.943) | 0.016a |
Serum concentration of tryptophan showed a significant association with rapid progression in diabetic nephropathy after adjusting with multiple models of confounding factors by multivariate logistic regression.
P < 0.05. Model 1 included the categorical variable of sex. Model 2 included the categorical variable of sex, and the continuous variable of age. Model 3 included the categorical variable of sex, and the continuous variables of age and duration of diabetes. Model 4 included the categorical variable of sex, and the continuous variables of age, duration of diabetes and glycated hemoglobin (HbA1c). Model 5 included the categorical variable of sex, and the continuous variables of age, duration of diabetes, HbA1c and hemoglobin (Hb). Model 6 included the categorical variable of sex, and the continuous variables of age, duration of diabetes, HbA1c, Hb and urine albumin‐to‐creatinine ratio (UACR). Model 7 included the categorical variable of sex, use of angiotensin‐converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), and the continuous variables of age, duration of diabetes, HbA1c, Hb and UACR.